GABRE siRNA_Lentivectors
- Known as:
- GABRE siRNA_Lentivectors
- Catalog number:
- i008412c
- Product Quantity:
- 500ng
- Category:
- -
- Supplier:
- ABM
- Gene target:
- GABRE siRNA_Lentivectors
Related genes to: GABRE siRNA_Lentivectors
- Gene:
- GABRE NIH gene
- Name:
- gamma-aminobutyric acid type A receptor epsilon subunit
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- Xq28
- Locus Type:
- gene with protein product
- Date approved:
- 1997-03-19
- Date modifiied:
- 2016-02-04
Related products to: GABRE siRNA_Lentivectors
Related articles to: GABRE siRNA_Lentivectors
- Climate change poses a significant threat to global biodiversity, altering species ranges and ecological dynamics. This study investigates the impact of climate change on Tabanus taeniola (Diptera: Tabanidae), a widely distributed horsefly with ecological importance in Africa and South America. Our objective was to model its current habitat suitability and predict future distribution shifts under various climatic scenarios. Using occurrence data from GBIF and and bioclimatic variables from WorldClim (BIO1-BIO19), we screened predictors for multicollinearity and calibrated MaxEnt models using a final subset of five variables. The model showed high accuracy, with an AUC of 0.918. Our findings identify the Minimum Temperature of the Coldest Month (BIO6) and Mean Temperature of Coldest Quarter (BIO11) as the key climatic drivers, with the species thriving in temperatures from 16 °C to 29 °C. Future projections, using the BCC-CSM2-MR and MRI-ESM2-0 models under SSP370 and SSP585 scenarios for 2050-2070, predict significant distributional shifts. We forecast a decline in optimal habitats in lowland tropical regions, with an expansion into temperate zones and higher altitudes in East Africa, South America, and parts of southern Europe. These projections indicate substantial redistribution toward higher elevations and temperate regions under future warming scenarios. - Source: PubMed
Publication date: 2026/07/03
Afifi Abdalrahman EGabre Refaat MAl-Khalaf Areej ASalem Abeer MAl Salameen FadilaNasser Mohamed G - Acute myeloid leukemia (AML) remains challenging to treat due to clinical heterogeneity and a lack of prognostic biomarkers. To address this, we developed a prognostic signature based on platelet-related genes (PRGs). By analyzing transcriptomic data from TCGA-LAML, GSE146173, and Beat AML 2.0 cohorts, we identified and validated an 11-gene signature (PSME2, PPIF, SYTL4, S100A4, CCND3, SMIM15, PARVB, STXBP5, KCNMB1, GABRE, SLC50A1) using LASSO-Cox regression. This model effectively stratified patients into high- and low-risk groups with distinct survival outcomes (p < 0.001) and demonstrated high predictive accuracy (1-/3-/5-year AUC: 0.832/0.782/0.880). High-risk patients exhibited immunosuppressive features, including upregulated immune checkpoints (CD274, CTLA4, HAVCR2, LAG3, PDCD1LG2, PDCD1), prominent monocyte infiltration, and reduced dendritic`11 cell activity. Drug sensitivity analysis suggested gefitinib, zebularine, and simvastatin as potential therapies for high-risk AML (p < 0.05). We further validated the signature's prognostic value using qPCR and clinical grouping. Notably, in vitro studies indicated that KCNMB1 facilitates AML progression. In conclusion, our robust PRG-based model elucidates the link between platelet biology, immune dysregulation, and therapeutic vulnerability in AML, offering clinical utility for risk stratification and treatment decisions. - Source: PubMed
Wu YiChen WanjiaGong SiqiWang JiajiaZhai Zhimin - BACKGROUND: Asymptomatic bacteriuria (ASB) is more widespread in postmenopausal women, especially among diabetic women. Nevertheless, a comprehensive definition of independent predictors of ASB in the general postmenopausal population and in the high-risk diabetic subgroup remains critical for management strategies. METHODS: The study was a cross-sectional examination of the prevalence of ASB and risk factors among 400 postmenopausal women (251 with diabetes, 149 without diabetes). Quantitative culture on midstream urine samples was done according to the standard microbiological practices. Structured questionnaires and medical records were used to get clinical and demographic data. Multivariate logistic regression was employed to determine independent factors associated with ASB. RESULTS: The general prevalence of ASB was 22.0% (n = 88), with a significantly higher rate in diabetic women compared to the control group (27.9% vs. 12.1%; p < 0.001). In the overall population, diabetes status (OR = 8.59; 95% CI: 1.99–37.0), HbA1c (OR = 2.52), and prior UTI history (OR = 3.98) were strong independent predictors. Within the diabetic subgroup, HbA1c (OR = 2.61; p < 0.001), history of UTIs (OR = 3.68), and age (OR = 1.13) remained the most significant predictors. Notably, the duration of diabetes was not a significant factor in this cohort. CONCLUSION: ASB is highly prevalent in diabetic postmenopausal women and strongly linked to poor glycaemic control, increased age, prior UTI, and exposure to antibiotics. These results highlight the importance of more focused prevention strategies and glycaemic control instead of general screening of ASB among this high-risk group. CLINICAL TRIAL NUMBER: Not applicable. - Source: PubMed
Publication date: 2026/04/13
Ashur Abir BenGashout AishaAbou-Aisha KhaledSalem Abeer MGabre Refaat M - Metastatic colorectal cancer (mCRC) remains a significant clinical challenge, with a 5-year survival rate of 10%. Approximately 40% of CRCs harbor mutations in the KRAS gene, leading to poor response to standard therapy. This underscores the crucial need for novel therapeutics targeting KRAS and overcoming the growing barrier of resistance. To address these critical challenges, we conducted a high-throughput screen to identify small molecules that synergize with the KRAS inhibitor MRTX1133 against CRC. Through screening a 2,652-kinase inhibitor library, we discovered that Osimertinib, an EGFR tyrosine kinase inhibitor, and its analogs strongly synergize with MRTX1133 against both parental and MRTX1133-resistant cells. The top compound from the screen, NT-1, is a chemical analog of Osimertinib. NT-1 strongly synergized with MRTX1133 to suppress EGFR/MAPK signaling and induce apoptosis in an MRTX1133-resistant patient-derived organoid model of CRC. We present novel small molecule combinations with the potential to overcome the limitations of KRAS inhibitors with direct clinical translational applications. - Source: PubMed
Publication date: 2026/04/08
Thielen NatalieWei NingNagai EmikoHouston MicheleAugenlicht Leonard HShin Alice EGabre Joel TRustgi Anil KHa GraceLaFave Lindsay MChu EdwardKitamura SeiyaKuang Chaoyuan - Use of minimally invasive surgical (MIS) techniques in the management of patients with inflammatory bowel disease (IBD) is increasing. The aim of this study was to compare postoperative morbidity in patients who underwent planned open procedures to those who had an unplanned conversion to open. - Source: PubMed
Publication date: 2026/02/19
Radomski Shannon NConsul MichaelStem MiloslawaBrown Lawrence BGabre-Kidan AlodiaGraham Ada EBafford Andrea CObias Vincent J